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with chronic alcoholic patients, but also in a context of chronic undernutrition
often hidden. The urinary disorders are not always at the forefront of
neurological semiology and can have a central or peripheral appearance.
They must be sought and managed in case of neurological impairment. Their
functional prognosis is often favorable.
http://dx.doi.org/10.1016/j.rehab.2012.07.985
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Objective.– Mestinon 60 mg is a parasympathomimetic, cholinesterase
inhibitor, which contains the active pyridostigmine which extends and enhances
the effects of muscarinic and nicotinic acetylcholine. It is usually used in the
treatment of myasthenia and intestinal atony, its use as a treatment for hypo-active
bladder of diabetic subject is recent and has shown excellent results.
The aim of this study is to provide the results of our experience.
Materials and methods.– Twenty-four diabetic patients with underactive bladder
confirmed by urodynamic studies were treated with Mestinon 60 mg dose to one
tablet twice per day, the evaluation was clinical, ultrasound and urodynamics.
Results.– The average patient age was 59 years, the median duration of diabetes
before treatment was 11 years, diabetes type I was interested in 88% of patients.
Treatment with 60 mg Mestinon restored a good clinical improvement with
urination, ultrasound (absence of post-voiding residue) and urodynamics in
96% of cases.
No adverse effects were noted except for one case of diarrhea. During the
median follow-up to 3 years, the results were stable.
Discussion.– Excellent results of Mestinon and lack of side effects, this
treatment needs to be prescribed as first line diabetes underactive bladder.
http://dx.doi.org/10.1016/j.rehab.2012.07.986P049-e
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Introduction.– Lower urinary tract symptoms (LUTS) are under-evaluated in
metabolic syndrome (MS). Many factors in this syndrome are implicated to
develop LUTS. The goals of this study were to analyze the frequency of the
LUTS in patients with MS and to examine the potential role of MS components
in the development of LUTS.
Methods.– We used urinary symptom profile (USP) to evaluate LUTS. The
physical examination included: weight, waist circumference, body mass index
(BMI) and blood pressure looking for orthostatic hypotension. The following
laboratory data were obtained: fasting blood sugar, postprandial glycemia,
glycosylated hemoglobin (HbA1c), HDL cholesterol, LDL cholesterol,
triglycerides and total cholesterol.
Results.– The average age of 34 enrolled patients was 56.2  9.2 years and
58.8% of patients were female. All patients had diabetic and hypertension
therapy. The mean of BMI was 30.2  4.8 and waist circumference
was 107.8  9.3 cm. USP total score was 8.3  6. Twenty-nine patients had
overactive bladder symptom, and 13 patients had urinary incontinence. The
overactive bladder USP score was positively correlated with age, waist
circumference, BMI and postprandial glycemia. The other components of MS
did not correlate with urinary symptoms. Total USP score and sub-score USP
were more alterated in patients with involvement of the automatic nervous
system, but not significantly.
Discussion.– The most frequency urinary symptom in the MS was overactive
bladder and urinary incontinence. The components of MS that influenced the
USP score were abdominal obesity and hyperglycemia. The hypothesis of
link between MS and overactive bladder in diabetic patients with MS is
plausible.
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